You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

  • Technology appraisal guidance
  • Reference number: TA218
  • Published:  23 March 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Appendix A: decision paper presented to the Institute's Guidance Executive

Appendix A: decision paper presented to the Institute's Guidance Executive Appendix A: decision paper presented to the Institute's Guidance Executive
23 April 2014
(101.95 Kb 29 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 22 April 2014

Back to top